IN2014MN01887A - - Google Patents
Info
- Publication number
- IN2014MN01887A IN2014MN01887A IN1887MUN2014A IN2014MN01887A IN 2014MN01887 A IN2014MN01887 A IN 2014MN01887A IN 1887MUN2014 A IN1887MUN2014 A IN 1887MUN2014A IN 2014MN01887 A IN2014MN01887 A IN 2014MN01887A
- Authority
- IN
- India
- Prior art keywords
- treatment
- prevention
- hsp60
- suppression
- diapep277
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Abstract
The present invention provides methods of prevention and treatment of Type 2 diabetes (T2D) using peptides and analogs of heat shock protein 60 (hsp60) and for suppression prevention and treatment of complications associated with T2D. The invention is exemplified using DiaPep277™ a peptide analog of human hsp60. The invention further relates treatment regimens useful for suppression prevention or treatment of T2D.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261605262P | 2012-03-01 | 2012-03-01 | |
PCT/IL2013/050174 WO2013128450A1 (en) | 2012-03-01 | 2013-02-28 | Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN01887A true IN2014MN01887A (en) | 2015-07-10 |
Family
ID=48050870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1887MUN2014 IN2014MN01887A (en) | 2012-03-01 | 2013-02-28 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20150018271A1 (en) |
EP (1) | EP2819692A1 (en) |
JP (1) | JP2015508812A (en) |
CN (1) | CN104244967A (en) |
AU (1) | AU2013227249A1 (en) |
CA (1) | CA2864655A1 (en) |
IN (1) | IN2014MN01887A (en) |
WO (1) | WO2013128450A1 (en) |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US5780034A (en) | 1989-03-14 | 1998-07-14 | Yeda Research And Development Co. Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus using heat shock protein determinents |
US5114844A (en) | 1989-03-14 | 1992-05-19 | Yeda Research And Development Co., Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus |
US5578303A (en) | 1989-03-14 | 1996-11-26 | Yeda Research And Development Co. Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus |
US6180103B1 (en) | 1994-12-21 | 2001-01-30 | Yeda Research And Development Co., Ltd. | Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes |
KR100400480B1 (en) | 1994-12-21 | 2003-12-31 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Peptide p277 analogs, pharmaceutical compositions and kits for the treatment or diagnosis of diabetes comprising them |
IL114407A0 (en) | 1995-06-30 | 1995-10-31 | Yeda Res & Dev | Novel peptides and pharmaceutical compositions comprising them |
US5993803A (en) | 1996-08-30 | 1999-11-30 | Yeda Research And Development Co., Ltd. | Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity |
US7316819B2 (en) | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
WO2003070761A1 (en) | 2002-02-19 | 2003-08-28 | Yeda Research And Development Co. Ltd. | Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation |
EP1718158B1 (en) * | 2004-01-28 | 2014-07-02 | Andromeda Bio Tech Ltd. | Hsp therapy in conjunction with a low antigenicity diet |
KR20050104152A (en) | 2004-04-28 | 2005-11-02 | 최승호 | Enhancing systems for poorly absorptive drugs |
EP1843788A4 (en) * | 2004-12-22 | 2009-11-18 | Centocor Ortho Biotech Inc | Glp-1 agonists, compositions, methods and uses |
EP1835933A4 (en) * | 2005-01-04 | 2015-01-07 | Yeda Res & Dev | Hsp60, hsp60 peptides and t cell vaccines for immunomodulation |
EP1858545A2 (en) * | 2005-03-04 | 2007-11-28 | Curedm Inc. | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
US8093207B2 (en) | 2005-12-09 | 2012-01-10 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
-
2013
- 2013-02-28 CA CA2864655A patent/CA2864655A1/en not_active Abandoned
- 2013-02-28 AU AU2013227249A patent/AU2013227249A1/en not_active Abandoned
- 2013-02-28 EP EP13715007.4A patent/EP2819692A1/en not_active Withdrawn
- 2013-02-28 IN IN1887MUN2014 patent/IN2014MN01887A/en unknown
- 2013-02-28 JP JP2014559346A patent/JP2015508812A/en active Pending
- 2013-02-28 US US14/379,758 patent/US20150018271A1/en not_active Abandoned
- 2013-02-28 WO PCT/IL2013/050174 patent/WO2013128450A1/en active Application Filing
- 2013-02-28 CN CN201380011731.XA patent/CN104244967A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2013128450A1 (en) | 2013-09-06 |
CA2864655A1 (en) | 2013-09-06 |
AU2013227249A1 (en) | 2014-09-11 |
EP2819692A1 (en) | 2015-01-07 |
JP2015508812A (en) | 2015-03-23 |
CN104244967A (en) | 2014-12-24 |
US20150018271A1 (en) | 2015-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201705114B (en) | Cysteine protease | |
ZA201705113B (en) | Cysteine protease | |
MX2021006017A (en) | Methods and compositions for treatment of disorders with follistatin polypeptides. | |
EP2528934A4 (en) | Aromatic-cationic peptides and uses of same | |
MX2016010951A (en) | Multimeric fc proteins. | |
MX2012009748A (en) | Use of transforming growth factor - beta 1 (tgf-î²1) inhibitor peptides for the treatment of corneal fibrosis and/or haze. | |
MX2019005272A (en) | Universal cancer peptides derived from telomerase. | |
IN2014CN04498A (en) | ||
NZ717035A (en) | Cortistatin analogues for the treatment of inflammatory and/or immune diseases | |
MX2017009595A (en) | Anti-senescence compounds and uses thereof. | |
MX2015005252A (en) | Novel method for treating cardiac infarction using hmgb1 fragment. | |
MX350445B (en) | Complement factor b analogs and their uses. | |
ZA201905851B (en) | Peptides and methods for the treatment of diabetes | |
MX2019003970A (en) | Immunogenic arginase peptides. | |
ZA201905891B (en) | Peptides for treatment of diabetes | |
SG10201805039UA (en) | Protease resistant peptides | |
EP2552462A4 (en) | Ccn3 peptides and analogs thereof for therapeutic use | |
SG11202000801QA (en) | Highly versatile method of presenting cyclic peptide on protein structure | |
GB2517354A (en) | Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy | |
MX2019008529A (en) | Apoc-ii mimetic peptides. | |
MX2016000448A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage. | |
EP3302531A4 (en) | Immune tolerant and non-immune tolerant elastin-like recombinant peptides and methods of use | |
MX362058B (en) | Synthetic pntx(19) peptide, pharmaceutical compositions and use. | |
NZ729514A (en) | Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis | |
GB201118201D0 (en) | Novel peptides |